TLDR
- Incyte stock jumps as EU panel backs Opzelura’s new AD indication.
- CHMP supports Opzelura use in adults with moderate atopic dermatitis.
- EU review could give Opzelura its second approved European indication.
- Phase 3 data showed stronger skin clearance and sustained itch relief.
- Safety data showed no major cardiovascular events or serious infections.
Incyte Corporation gained 5.37% to $113.30 after a European panel supported a new Opzelura indication. The recommendation covers adults with moderate atopic dermatitis who cannot use standard topical therapies effectively. The decision moves Opzelura closer to broader regulatory approval across the European Union.
CHMP Backs Opzelura for Moderate Atopic Dermatitis
The European Medicines Agency’s CHMP recommended approving Opzelura cream for moderate atopic dermatitis in adults. The proposed indication targets patients who receive inadequate results from topical corticosteroids and topical calcineurin inhibitors. It also covers patients who cannot use those treatments because of intolerance or medical restrictions.
The European Commission will now review the committee’s recommendation before issuing its final decision. The Commission grants centralized marketing approvals that apply across all European Union member states. A final approval would establish Opzelura as a non-steroidal topical JAK treatment for eligible adults.
Opzelura already holds European approval for non-segmental vitiligo with facial involvement. That authorization covers adults and adolescents aged 12 years and older. An atopic dermatitis approval would give the product its second approved indication in Europe.
Phase 3 Study Supports Regulatory Recommendation
Incyte based the application on results from the Phase 3 TRuE-AD4 clinical study. The company also provided supporting evidence from the TRuE-AD1 and TRuE-AD2 trials. These studies assessed ruxolitinib cream’s safety and effectiveness in adults with atopic dermatitis.
TRuE-AD4 met both primary endpoints after eight weeks of treatment. More patients receiving ruxolitinib cream achieved at least a 75% improvement in eczema severity. More treated patients also reached clear or almost clear skin with meaningful improvement from baseline.
The treatment showed early improvements in itching, with some patients reporting relief by the second day. At Week 24, 84.3% of patients achieved the targeted eczema severity improvement. 70.6% achieved the investigator-defined treatment success measure during as-needed therapy.
Opzelura Data Show Sustained Skin and Itch Improvements
The study recorded a clear reduction in the average affected body surface area. Average coverage fell from 15.1% at baseline to 2.5% after eight weeks. That level remained unchanged through Week 24, indicating sustained control during continued treatment.
Itch relief also remained strong throughout the study’s 24-week treatment period. About 74.3% of patients achieved meaningful itch improvement at Week 8. The rate reached 64.7% at Week 24 while patients followed an as-needed treatment schedule.
Patients also reported improved quality of life after receiving ruxolitinib cream. Average Dermatology Life Quality Index scores fell from 19.3 to 4.3 by Week 8. In comparison, the vehicle group’s average score declined from 19.1 to 10.7.
Safety Results and European Treatment Context
Ruxolitinib cream showed a generally well-tolerated safety profile during the study. Researchers reported no serious infections, major cardiovascular events, malignancies or thromboses during 24 weeks. Upper respiratory infections and nasopharyngitis represented the most common treatment-emergent adverse events.
Atopic dermatitis causes recurring inflammation, severe itching and visible skin lesions. The condition affects up to 4% of adults worldwide and remains common across Europe. European prevalence estimates range between 4.4% and 7.1% among adults.
Many adults with moderate disease do not gain sufficient control from existing topical therapies. The proposed indication would provide another local treatment before patients move to systemic medicines. A European Commission approval would broaden Opzelura’s commercial and clinical role within Incyte’s dermatology portfolio.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
